Category Archives: Parkinson’s Treatment

By Briana Vannozzi Correspondent You cant see tremors in Paul Detlefsens hands now, but a decade ago, the outlook for this 43-year-old Parkinsons disease patient looked a lot different. My symptoms were mostly in the right arm, sever tremors, he said. Detlefsen underwent whats called deep brain stimulation surgery. We first showed you the procedure two years ago, on another patient at JFK Neuroscience Institute. Surgically implanted electrodes on the brain send impulses that block signals causing tremors and involuntary movements. The 20-year-old procedure is wildly successful, with just one downfall. Patients were given a bulky remote control generator to manage the system. It was tricky to use alone and required in-office appointments for adjustments. Until now where brain waves meet touch pad. So we convert from the older system to an iPod where they can remotely go up and down on their parameters even at home, said neurosurgeon Dr. Asif Bashir. Detlefsen is the first patient in the U.S. to marry the old system to new, managing his DBSfrom an iPod Touch. Specifically without getting too technical, they can adjust the frequency, amplitude, pulse width, so theres some scientific electronic features that they can adjust to help their symptoms, … Continue reading →

BBC News Bangor Uni PC games research to help Parkinson's treatment BBC News Research into how computer games stimulate the brain could be used to help treat Parkinson's disease. The study looked at the effects of touch screen "spatial reasoning games" on the part of the brain used to control movement. Early research involving ... and more » Original post: Bangor Uni PC games research to help Parkinson's treatment - BBC News … Continue reading →

Scientists from Sweden say they have made significant progress in the search for a new treatment for Parkinsons disease. Though the research, published in Nature Biotechnology, is still preliminary and the therapy not yet ready to be tested in humans, experts say it could one day help the millions of people living with the neurodegenerative disease. Researchers from the Karolinska Institute tested whether certain brain cells could be manipulated to take on the role of those destroyed by Parkinsons. Play Video The longest fight of Muhammad Ali's life was with Parkinson's disease. Even when the heavyweight champion was at his peak, signs of the disorder ... They first showed in laboratory experiments that it was possible to convert non-neural human brain cells called astrocytes into dopamine neurons, which degenerate and die in the brains of people suffering from Parkinsons disease. These are two specialized cells that do not spontaneously convert into one another, study author Ernest Arenas, a professor at Karolinska Institutes Department of medical biochemistry and biophysics, told CBS News. However, when we used diverse chemicals and genes important for the development of immature brain cells into functional dopamine neurons, we found that it was possible to convert astrocytes … Continue reading →

2017 marks 200 years since James Parkinson, an English apothecary, surgeon, geologist and sometime political activist, published a paper that defined his legacy. An Essay on the Shaking Palsy described a syndrome that caused wide-ranging problems that affected how people move, feel, speak, think and even look. This constellation of symptoms was probably as old as the human race, but Parkinson was the first to scientifically characterize it. Today we know it as his disease. Its estimated that five million people worldwide are currently living with Parkinson's disease, or PD, which we now know kills the neurons that produce dopamine (a critical chemical in brain function) among other changes in the brain. Most people get it around age 60, though it is also seen in people as young as their 20s. The disease is progressive, meaning that it gets inexorably worse over time, and many live with it for decades. Estimated prevalence numbers are likely on the low side because PD is frequently misdiagnosed and can lead to isolation and social withdrawal. Its interesting to imagine what Dr. Parkinson would think about what two centuries of scientific exploration have done to bring us closer to a cure for PD. On … Continue reading →

Posted: Friday, April 14 2017 4:24 AM EDT2017-04-14 08:24:05 GMT Updated: Friday, April 14 2017 4:24 AM EDT2017-04-14 08:24:05 GMT Canadian Prime Minister Justin Trudeau's government has introduced legislation to let adults to possess 30 grams of marijuana in public. Canadian Prime Minister Justin Trudeau's government has introduced legislation to let adults to possess 30 grams of marijuana in public. Posted: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:09 GMT Updated: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:09 GMT What to know about new advice on prostate cancer test. What to know about new advice on prostate cancer test. Posted: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:05 GMT Updated: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:05 GMT A new study says bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties. A new study says bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties. Posted: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:04 GMT Updated: Friday, April 14 2017 3:54 AM EDT2017-04-14 07:54:04 GMT President Donald Trump has signed legislation that lets states withhold federal family … Continue reading →

MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, is pleased to note the news from its partner Zambon, that it has entered into a partnership with Valeo Pharma for the Canadian market to provide the 100,000 patients living with Parkinsons access to Xadago (safinamide). Canada represents one of the eight major markets. *World Parkinson's Day (WPD) is observed every year on April 11, the birthday of Dr. James Parkinson, the English physician who first described the symptoms of the disease, in 1817; thus, the 2017 WPD marks 200 years since publication of An Essay on the Shaking Palsy. The full text of the announcement from Zambon and Valeo Pharma is as follows: Valeo Pharma and Zambon form partnership for Parkinsons Disease Treatment Xadago (safinamide) in Canada April 11, 2017 Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada, today announced a strategic agreement to commercialize Xadago (safinamide) for the treatment of Parkinsons disease in … Continue reading →

Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinsons that is attracting top partners worldwide. Right on time forWorld Parkinsons Daytoday, Mission Therapeutics has announced it has been awarded a research grant from theMichael J. Fox Foundation in the US. Named after its founder, the star of Back to the Future, the Foundation represents the largest nonprofit fund dedicated to finding a cure for Parkinsons worldwide. No figure has been disclosed, but the funds will be directed at testingUSP30 inhibitors in cell lines derived from Parkinsons patients developed by Professor Richard Wade-Martins at the University of Oxford. Anker Lundemose [The goal is] to determine which Parkinsons subgroup the drug is working on, CEO of Mission Therapeutics, Anker Lundemose, told us. USP30 affects the Parkin pathway, which is mutated in certain Parkinsons patients. [We aim] to identify if this only works in subsets or in all Parkinsons patients. USP30 is a protein involved in the regulation of mitophagy. All mitochondria in the cell have a life span of approximately 40 days, then its degraded in the lysosomes. If you inhibit USP30 youll increase the turnover, explains Lundemose. Basically put them in the garbage … Continue reading →

April 11 Manitex Capital Inc: * Manitex Capital Inc's affiliate, Valeo Pharma Inc, announces partnership for a parkinson's disease treatment * Manitex Capital- entered into partnership with Zambon s.p.a. For exclusive Canadian rights to commercialize new parkinson's disease product Xadago * Manitex Capital Inc says valeo pharma will pay zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales * Manitex Capital - under terms of deal, Valeo Pharma to be responsible for all regulatory, sales, marketing, quality, distribution activities in Canada * Manitex Capital - agreement grants Valeo Pharma exclusive rights to commercialise Zambon's parkinson's disease product, licensed from Newron Source text for Eikon: Further company coverage: * Allies see Trump missile strikes as reversal of isolationism April 11 Neel Kashkari, the chief of the Minneapolis Federal Reserve who was the lone dissenter on the Fed's rate hike last month, repeated Tuesday his view that there is still slack in the labor market and that inflation is still lower than it should be. Link: BRIEF-Manitex Capital's affiliate, Valeo Pharma announces partnership for parkinson's disease treatment - Reuters … Continue reading →

NEW YORK, April 11, 2017 /PRNewswire/ --AbleTo, Inc., the leading technology-enabled provider of behavioral health treatment proven to improve patient outcomes, increase access, and lower healthcare costs, announced today two additional treatment programs to address the unique behavioral health challenges faced by patients with Parkinson's disease and their caregivers. These programs are customized to treat the depression, anxiety, apathy, and sleep disturbances commonly experienced by individuals suffering from Parkinson's disease, utilizing AbleTo's proven care delivery model that integrates human care providers and digital capabilities in a structured, evidenced-based treatment offering. The 8-week Parkinson's disease program will be available in the summer of 2017. Individuals interested in learning more about the program can contact Info@AbleTo.com Effects of Depression on Parkinson's Disease Patients and their CaregiversThe National Parkinson Foundation estimates that at least 50 percent of those diagnosed with Parkinson's disease will experience some form of depression during their illness. Research published by the American Psychological Association found that depression has been linked to significant decreases in quality of life, greater impairment in completing activities of daily living, more rapid physical and cognitive decline, increased need for treatment of motor symptoms, greater disability, and increased caregiver burden. AbleTo's 8-week program was developed … Continue reading →

MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (Newron) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, is pleased to note the news from its partner Zambon, that it has entered into a partnership with Valeo Pharma for the Canadian market to provide the 100,000 patients living with Parkinsons access to Xadago (safinamide). Canada represents one of the eight major markets. *World Parkinson's Day (WPD) is observed every year on April 11, the birthday of Dr. James Parkinson, the English physician who first described the symptoms of the disease, in 1817; thus, the 2017 WPD marks 200 years since publication of An Essay on the Shaking Palsy. The full text of the announcement from Zambon and Valeo Pharma is as follows: Valeo Pharma and Zambon form partnership for Parkinsons Disease Treatment Xadago (safinamide) in Canada April 11, 2017 Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada, today announced a strategic agreement to commercialize Xadago (safinamide) for the treatment of Parkinsons disease in … Continue reading →